A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
Open Access
- 6 July 2004
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (4), 627-632
- https://doi.org/10.1038/sj.bjc.6602000
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancerLung Cancer, 2002
- Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosisThe Lancet Oncology, 2002
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinomaSeminars in Oncology, 2002
- Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancerAnti-Cancer Drugs, 2001
- A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanesInternational Journal of Cancer, 2001
- Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancerEuropean Journal Of Cancer, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Severe non-haematological toxicity after treatment with gemcitabineZeitschrift für Krebsforschung und Klinische Onkologie, 1999
- A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerAnnals of Oncology, 1998